Summary

The global market for Trivalent Inactivated Influenza Vaccine was estimated to be worth US$ 3777 million in 2024 and is forecast to a readjusted size of US$ 6262 million by 2031 with a CAGR of 7.6% during the forecast period 2025-2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Trivalent Inactivated Influenza Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Trivalent Inactivated Influenza Vaccine by region & country, by Type, and by Application.

The Trivalent Inactivated Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Trivalent Inactivated Influenza Vaccine.

Market Segmentation
By Company
AstraZeneca
Sanofi S.A
Abbott
GlaxoSmithKline
Merck
Novartis
Pfizer
Serum Institute of India
CSL Limited
Segment by Type
Nasal Spray
Intramuscular Injection
Intradermal Injection
Segment by Application
Hospital
Clinic
Public Health Agency
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Trivalent Inactivated Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Trivalent Inactivated Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Trivalent Inactivated Influenza Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Trivalent Inactivated Influenza Vaccine Product Introduction
1.2 Global Trivalent Inactivated Influenza Vaccine Market Size Forecast
1.2.1 Global Trivalent Inactivated Influenza Vaccine Sales Value (2020-2031)
1.2.2 Global Trivalent Inactivated Influenza Vaccine Sales Volume (2020-2031)
1.2.3 Global Trivalent Inactivated Influenza Vaccine Sales Price (2020-2031)
1.3 Trivalent Inactivated Influenza Vaccine Market Trends & Drivers
1.3.1 Trivalent Inactivated Influenza Vaccine Industry Trends
1.3.2 Trivalent Inactivated Influenza Vaccine Market Drivers & Opportunity
1.3.3 Trivalent Inactivated Influenza Vaccine Market Challenges
1.3.4 Trivalent Inactivated Influenza Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Trivalent Inactivated Influenza Vaccine Players Revenue Ranking (2024)
2.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Company (2020-2025)
2.3 Global Trivalent Inactivated Influenza Vaccine Players Sales Volume Ranking (2024)
2.4 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Company Players (2020-2025)
2.5 Global Trivalent Inactivated Influenza Vaccine Average Price by Company (2020-2025)
2.6 Key Manufacturers Trivalent Inactivated Influenza Vaccine Manufacturing Base and Headquarters
2.7 Key Manufacturers Trivalent Inactivated Influenza Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Trivalent Inactivated Influenza Vaccine
2.9 Trivalent Inactivated Influenza Vaccine Market Competitive Analysis
2.9.1 Trivalent Inactivated Influenza Vaccine Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Trivalent Inactivated Influenza Vaccine Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Trivalent Inactivated Influenza Vaccine as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Nasal Spray
3.1.2 Intramuscular Injection
3.1.3 Intradermal Injection
3.2 Global Trivalent Inactivated Influenza Vaccine Sales Value by Type
3.2.1 Global Trivalent Inactivated Influenza Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Trivalent Inactivated Influenza Vaccine Sales Value, by Type (2020-2031)
3.2.3 Global Trivalent Inactivated Influenza Vaccine Sales Value, by Type (%) (2020-2031)
3.3 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Type
3.3.1 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Trivalent Inactivated Influenza Vaccine Sales Volume, by Type (2020-2031)
3.3.3 Global Trivalent Inactivated Influenza Vaccine Sales Volume, by Type (%) (2020-2031)
3.4 Global Trivalent Inactivated Influenza Vaccine Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Public Health Agency
4.1.4 Others
4.2 Global Trivalent Inactivated Influenza Vaccine Sales Value by Application
4.2.1 Global Trivalent Inactivated Influenza Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Trivalent Inactivated Influenza Vaccine Sales Value, by Application (2020-2031)
4.2.3 Global Trivalent Inactivated Influenza Vaccine Sales Value, by Application (%) (2020-2031)
4.3 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Application
4.3.1 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Trivalent Inactivated Influenza Vaccine Sales Volume, by Application (2020-2031)
4.3.3 Global Trivalent Inactivated Influenza Vaccine Sales Volume, by Application (%) (2020-2031)
4.4 Global Trivalent Inactivated Influenza Vaccine Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Trivalent Inactivated Influenza Vaccine Sales Value by Region
5.1.1 Global Trivalent Inactivated Influenza Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Trivalent Inactivated Influenza Vaccine Sales Value by Region (2020-2025)
5.1.3 Global Trivalent Inactivated Influenza Vaccine Sales Value by Region (2026-2031)
5.1.4 Global Trivalent Inactivated Influenza Vaccine Sales Value by Region (%), (2020-2031)
5.2 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Region
5.2.1 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Region (2020-2025)
5.2.3 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Region (2026-2031)
5.2.4 Global Trivalent Inactivated Influenza Vaccine Sales Volume by Region (%), (2020-2031)
5.3 Global Trivalent Inactivated Influenza Vaccine Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
5.4.2 North America Trivalent Inactivated Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
5.5.2 Europe Trivalent Inactivated Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
5.6.2 Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
5.7.2 South America Trivalent Inactivated Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
5.8.2 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Trivalent Inactivated Influenza Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Trivalent Inactivated Influenza Vaccine Sales Value
6.2.1 Key Countries/Regions Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.2.2 Key Countries/Regions Trivalent Inactivated Influenza Vaccine Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.3.2 United States Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.4.2 Europe Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.5.2 China Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.5.3 China Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.6.2 Japan Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.7.2 South Korea Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.8.2 Southeast Asia Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Trivalent Inactivated Influenza Vaccine Sales Value, 2020-2031
6.9.2 India Trivalent Inactivated Influenza Vaccine Sales Value by Type (%), 2024 VS 2031
6.9.3 India Trivalent Inactivated Influenza Vaccine Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Information
7.1.2 AstraZeneca Introduction and Business Overview
7.1.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 AstraZeneca Trivalent Inactivated Influenza Vaccine Product Offerings
7.1.5 AstraZeneca Recent Development
7.2 Sanofi S.A
7.2.1 Sanofi S.A Company Information
7.2.2 Sanofi S.A Introduction and Business Overview
7.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Offerings
7.2.5 Sanofi S.A Recent Development
7.3 Abbott
7.3.1 Abbott Company Information
7.3.2 Abbott Introduction and Business Overview
7.3.3 Abbott Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Abbott Trivalent Inactivated Influenza Vaccine Product Offerings
7.3.5 Abbott Recent Development
7.4 GlaxoSmithKline
7.4.1 GlaxoSmithKline Company Information
7.4.2 GlaxoSmithKline Introduction and Business Overview
7.4.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Offerings
7.4.5 GlaxoSmithKline Recent Development
7.5 Merck
7.5.1 Merck Company Information
7.5.2 Merck Introduction and Business Overview
7.5.3 Merck Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Merck Trivalent Inactivated Influenza Vaccine Product Offerings
7.5.5 Merck Recent Development
7.6 Novartis
7.6.1 Novartis Company Information
7.6.2 Novartis Introduction and Business Overview
7.6.3 Novartis Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Novartis Trivalent Inactivated Influenza Vaccine Product Offerings
7.6.5 Novartis Recent Development
7.7 Pfizer
7.7.1 Pfizer Company Information
7.7.2 Pfizer Introduction and Business Overview
7.7.3 Pfizer Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Pfizer Trivalent Inactivated Influenza Vaccine Product Offerings
7.7.5 Pfizer Recent Development
7.8 Serum Institute of India
7.8.1 Serum Institute of India Company Information
7.8.2 Serum Institute of India Introduction and Business Overview
7.8.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Offerings
7.8.5 Serum Institute of India Recent Development
7.9 CSL Limited
7.9.1 CSL Limited Company Information
7.9.2 CSL Limited Introduction and Business Overview
7.9.3 CSL Limited Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 CSL Limited Trivalent Inactivated Influenza Vaccine Product Offerings
7.9.5 CSL Limited Recent Development
8 Industry Chain Analysis
8.1 Trivalent Inactivated Influenza Vaccine Industrial Chain
8.2 Trivalent Inactivated Influenza Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Trivalent Inactivated Influenza Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Trivalent Inactivated Influenza Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer